Literature DB >> 24748425

The increased risk of venous thromboembolism by advancing age cannot be attributed to the higher incidence of cancer in the elderly: the Tromsø study.

Kristine Blix1, Sigrid K Brækkan, Saskia le Cessie, Finn E Skjeldestad, Suzanne C Cannegieter, John-Bjarne Hansen.   

Abstract

UNLABELLED: Whether the high incidence of venous thromboembolism (VTE) in the elderly can be attributed to cancer is not well studied. We assessed the impact of cancer on risk of VTE in young, middle-aged and elderly. 26,094 subjects without a history of cancer or VTE were recruited from the Tromsø study. Incident cancer (n = 2,290) and VTE (n = 531) were recorded from baseline (1994-1995) through December 31st, 2009. Cox regression with cancer as time-varying exposure was used to calculate hazard ratios with 95 % confidence intervals (CI). Overt cancer was associated with a fivefold (95 %CI 4.3, 6.7) increased risk of VTE, with an age-dependent gradient from 26-fold (95 %CI 12.1, 56.5) increased in the young, ninefold (95 % CI 6.6, 12.7) increased in the middle-aged, and threefold (95 % CI 2.5, 4.5) increased risk in the elderly. The population attributable risks were 14, 27 and 18 %, respectively.
CONCLUSION: The relative risk of VTE by cancer were higher in young compared to elderly subjects, but the proportion of VTEs in the population due to cancer did not differ much across age groups. Our findings indicate that the increased risk of VTE by advancing age cannot be attributed to higher incidence of cancer in the elderly.

Entities:  

Mesh:

Year:  2014        PMID: 24748425     DOI: 10.1007/s10654-014-9902-7

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  25 in total

1.  Incidence of venous thromboembolism and its effect on survival among patients with common cancers.

Authors:  Helen K Chew; Theodore Wun; Danielle Harvey; Hong Zhou; Richard H White
Journal:  Arch Intern Med       Date:  2006-02-27

2.  Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data.

Authors:  N Levitan; A Dowlati; S C Remick; H I Tahsildar; L D Sivinski; R Beyth; A A Rimm
Journal:  Medicine (Baltimore)       Date:  1999-09       Impact factor: 1.889

3.  Accounting for death as a competing risk in cancer-associated thrombosis studies.

Authors:  Federico Campigotto; Donna Neuberg; Jeffrey I Zwicker
Journal:  Thromb Res       Date:  2012-04       Impact factor: 3.944

4.  Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy.

Authors:  A A Khorana; C W Francis; E Culakova; N M Kuderer; G H Lyman
Journal:  J Thromb Haemost       Date:  2007-03       Impact factor: 5.824

5.  Body height and risk of venous thromboembolism: The Tromsø Study.

Authors:  Sigrid K Braekkan; Knut H Borch; Ellisiv B Mathiesen; Inger Njølstad; Tom Wilsgaard; John-Bjarne Hansen
Journal:  Am J Epidemiol       Date:  2010-04-23       Impact factor: 4.897

6.  Venous thromboembolism discharge diagnoses in the Danish National Patient Registry should be used with caution.

Authors:  Marianne Tang Severinsen; Søren Risom Kristensen; Kim Overvad; Claus Dethlefsen; Anne Tjønneland; Søren Paaske Johnsen
Journal:  J Clin Epidemiol       Date:  2010-02       Impact factor: 6.437

Review 7.  Venous thrombosis: a multicausal disease.

Authors:  F R Rosendaal
Journal:  Lancet       Date:  1999-04-03       Impact factor: 79.321

8.  Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.

Authors:  Paolo Prandoni; Anthonie W A Lensing; Andrea Piccioli; Enrico Bernardi; Paolo Simioni; Bruno Girolami; Antonio Marchiori; Paola Sabbion; Martin H Prins; Franco Noventa; Antonio Girolami
Journal:  Blood       Date:  2002-07-12       Impact factor: 22.113

9.  Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases.

Authors:  Alex J Walker; Tim R Card; Joe West; Colin Crooks; Matthew J Grainge
Journal:  Eur J Cancer       Date:  2012-11-09       Impact factor: 9.162

Review 10.  Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis.

Authors:  Freesia Horsted; Joe West; Matthew J Grainge
Journal:  PLoS Med       Date:  2012-07-31       Impact factor: 11.069

View more
  4 in total

1.  The Rotterdam Study: 2016 objectives and design update.

Authors:  Albert Hofman; Guy G O Brusselle; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; M Arfan Ikram; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Ch Stricker; Henning W Tiemeier; André G Uitterlinden; Meike W Vernooij
Journal:  Eur J Epidemiol       Date:  2015-09-19       Impact factor: 8.082

2.  Venous thromboembolism in chronic lymphocytic leukemia: a Danish nationwide cohort study.

Authors:  Inger Lise Gade; Signe Juul Riddersholm; Ilse Christiansen; Annika Rewes; Mikael Frederiksen; Lisbeth Enggaard; Christian Bjørn Poulsen; Olav Jonas Bergmann; Dorte Balle Gillström; Robert Schou Pedersen; Linda Nielsen; Helle Højmark Eriksen; Christian Torp-Pedersen; Søren Risom Kristensen; Marianne Tang Severinsen
Journal:  Blood Adv       Date:  2018-11-13

3.  The European Hematology Association Roadmap for European Hematology Research: a consensus document.

Authors:  Andreas Engert; Carlo Balduini; Anneke Brand; Bertrand Coiffier; Catherine Cordonnier; Hartmut Döhner; Thom Duyvené de Wit; Sabine Eichinger; Willem Fibbe; Tony Green; Fleur de Haas; Achille Iolascon; Thierry Jaffredo; Francesco Rodeghiero; Gilles Salles; Jan Jacob Schuringa
Journal:  Haematologica       Date:  2016-01-27       Impact factor: 9.941

4.  Quantification of Treatment Effect Modification on Both an Additive and Multiplicative Scale.

Authors:  Nicolas Girerd; Muriel Rabilloud; Philippe Pibarot; Patrick Mathieu; Pascal Roy
Journal:  PLoS One       Date:  2016-04-05       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.